IBDEI0TN ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,38997,1,4,0)
 ;;=4^M30.1
 ;;^UTILITY(U,$J,358.3,38997,2)
 ;;=^5011739
 ;;^UTILITY(U,$J,358.3,38998,0)
 ;;=M34.1^^109^1612^89
 ;;^UTILITY(U,$J,358.3,38998,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38998,1,3,0)
 ;;=3^CR(E)ST syndrome
 ;;^UTILITY(U,$J,358.3,38998,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,38998,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,38999,0)
 ;;=D89.1^^109^1612^100
 ;;^UTILITY(U,$J,358.3,38999,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,38999,1,3,0)
 ;;=3^Cryoglobulinemia
 ;;^UTILITY(U,$J,358.3,38999,1,4,0)
 ;;=4^D89.1
 ;;^UTILITY(U,$J,358.3,38999,2)
 ;;=^29577
 ;;^UTILITY(U,$J,358.3,39000,0)
 ;;=M33.90^^109^1612^101
 ;;^UTILITY(U,$J,358.3,39000,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39000,1,3,0)
 ;;=3^Dermatoplymyostis, unsp, organ invlvmnt, unspec
 ;;^UTILITY(U,$J,358.3,39000,1,4,0)
 ;;=4^M33.90
 ;;^UTILITY(U,$J,358.3,39000,2)
 ;;=^5011774
 ;;^UTILITY(U,$J,358.3,39001,0)
 ;;=L93.0^^109^1612^102
 ;;^UTILITY(U,$J,358.3,39001,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39001,1,3,0)
 ;;=3^Discoid lupus erythematosus
 ;;^UTILITY(U,$J,358.3,39001,1,4,0)
 ;;=4^L93.0
 ;;^UTILITY(U,$J,358.3,39001,2)
 ;;=^5009467
 ;;^UTILITY(U,$J,358.3,39002,0)
 ;;=M1A.20X1^^109^1612^153
 ;;^UTILITY(U,$J,358.3,39002,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39002,1,3,0)
 ;;=3^Gout, chron, drug-inducd, unsp site, w/tophus (tophi)
 ;;^UTILITY(U,$J,358.3,39002,1,4,0)
 ;;=4^M1A.20X1
 ;;^UTILITY(U,$J,358.3,39002,2)
 ;;=^5010926
 ;;^UTILITY(U,$J,358.3,39003,0)
 ;;=M10.9^^109^1612^158
 ;;^UTILITY(U,$J,358.3,39003,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39003,1,3,0)
 ;;=3^Gout, unspecified
 ;;^UTILITY(U,$J,358.3,39003,1,4,0)
 ;;=4^M10.9
 ;;^UTILITY(U,$J,358.3,39003,2)
 ;;=^5010404
 ;;^UTILITY(U,$J,358.3,39004,0)
 ;;=M1A.00X1^^109^1612^154
 ;;^UTILITY(U,$J,358.3,39004,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39004,1,3,0)
 ;;=3^Gout, chron, idiopath, unspec site, w/ tophus (tophi)
 ;;^UTILITY(U,$J,358.3,39004,1,4,0)
 ;;=4^M1A.00X1
 ;;^UTILITY(U,$J,358.3,39004,2)
 ;;=^5010858
 ;;^UTILITY(U,$J,358.3,39005,0)
 ;;=M10.00^^109^1612^157
 ;;^UTILITY(U,$J,358.3,39005,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39005,1,3,0)
 ;;=3^Gout, idiopath, unspec site
 ;;^UTILITY(U,$J,358.3,39005,1,4,0)
 ;;=4^M10.00
 ;;^UTILITY(U,$J,358.3,39005,2)
 ;;=^5010284
 ;;^UTILITY(U,$J,358.3,39006,0)
 ;;=Z00.6^^109^1612^1
 ;;^UTILITY(U,$J,358.3,39006,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39006,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,39006,1,4,0)
 ;;=4^Z00.6
 ;;^UTILITY(U,$J,358.3,39006,2)
 ;;=^5062608
 ;;^UTILITY(U,$J,358.3,39007,0)
 ;;=Z00.6^^109^1612^134
 ;;^UTILITY(U,$J,358.3,39007,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39007,1,3,0)
 ;;=3^Encntr for exam for nrml cmprsn & ctrl in clin rsrch prog
 ;;^UTILITY(U,$J,358.3,39007,1,4,0)
 ;;=4^Z00.6
 ;;^UTILITY(U,$J,358.3,39007,2)
 ;;=^5062608
 ;;^UTILITY(U,$J,358.3,39008,0)
 ;;=M79.7^^109^1612^136
 ;;^UTILITY(U,$J,358.3,39008,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39008,1,3,0)
 ;;=3^Fibromyalgia
 ;;^UTILITY(U,$J,358.3,39008,1,4,0)
 ;;=4^M79.7
 ;;^UTILITY(U,$J,358.3,39008,2)
 ;;=^46261
 ;;^UTILITY(U,$J,358.3,39009,0)
 ;;=M06.4^^109^1612^164
 ;;^UTILITY(U,$J,358.3,39009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39009,1,3,0)
 ;;=3^Inflammatory polyarthropathy
 ;;^UTILITY(U,$J,358.3,39009,1,4,0)
 ;;=4^M06.4
 ;;^UTILITY(U,$J,358.3,39009,2)
 ;;=^5010120
 ;;^UTILITY(U,$J,358.3,39010,0)
 ;;=M54.5^^109^1612^191
 ;;^UTILITY(U,$J,358.3,39010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39010,1,3,0)
 ;;=3^Low back pain
 ;;^UTILITY(U,$J,358.3,39010,1,4,0)
 ;;=4^M54.5
 ;;^UTILITY(U,$J,358.3,39010,2)
 ;;=^5012311
 ;;^UTILITY(U,$J,358.3,39011,0)
 ;;=M35.5^^109^1612^195
 ;;^UTILITY(U,$J,358.3,39011,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39011,1,3,0)
 ;;=3^Multifocal fibrosclerosis
 ;;^UTILITY(U,$J,358.3,39011,1,4,0)
 ;;=4^M35.5
 ;;^UTILITY(U,$J,358.3,39011,2)
 ;;=^5011794
 ;;^UTILITY(U,$J,358.3,39012,0)
 ;;=M79.1^^109^1612^196
 ;;^UTILITY(U,$J,358.3,39012,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39012,1,3,0)
 ;;=3^Myalgia
 ;;^UTILITY(U,$J,358.3,39012,1,4,0)
 ;;=4^M79.1
 ;;^UTILITY(U,$J,358.3,39012,2)
 ;;=^5013321
 ;;^UTILITY(U,$J,358.3,39013,0)
 ;;=G73.7^^109^1612^197
 ;;^UTILITY(U,$J,358.3,39013,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39013,1,3,0)
 ;;=3^Myopathy in diseases classified elsewhere
 ;;^UTILITY(U,$J,358.3,39013,1,4,0)
 ;;=4^G73.7
 ;;^UTILITY(U,$J,358.3,39013,2)
 ;;=^5004103
 ;;^UTILITY(U,$J,358.3,39014,0)
 ;;=M71.50^^109^1612^66
 ;;^UTILITY(U,$J,358.3,39014,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39014,1,3,0)
 ;;=3^Bursitis, NEC, unspec site, oth
 ;;^UTILITY(U,$J,358.3,39014,1,4,0)
 ;;=4^M71.50
 ;;^UTILITY(U,$J,358.3,39014,2)
 ;;=^5013190
 ;;^UTILITY(U,$J,358.3,39015,0)
 ;;=E83.59^^109^1612^104
 ;;^UTILITY(U,$J,358.3,39015,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39015,1,3,0)
 ;;=3^Disorders of calcium metabolism, oth
 ;;^UTILITY(U,$J,358.3,39015,1,4,0)
 ;;=4^E83.59
 ;;^UTILITY(U,$J,358.3,39015,2)
 ;;=^5003006
 ;;^UTILITY(U,$J,358.3,39016,0)
 ;;=L93.2^^109^1612^187
 ;;^UTILITY(U,$J,358.3,39016,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39016,1,3,0)
 ;;=3^Local lupus erythematosus, oth
 ;;^UTILITY(U,$J,358.3,39016,1,4,0)
 ;;=4^L93.2
 ;;^UTILITY(U,$J,358.3,39016,2)
 ;;=^5009469
 ;;^UTILITY(U,$J,358.3,39017,0)
 ;;=L40.59^^109^1612^209
 ;;^UTILITY(U,$J,358.3,39017,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39017,1,3,0)
 ;;=3^Psoriatic arthropathy, oth
 ;;^UTILITY(U,$J,358.3,39017,1,4,0)
 ;;=4^L40.59
 ;;^UTILITY(U,$J,358.3,39017,2)
 ;;=^5009170
 ;;^UTILITY(U,$J,358.3,39018,0)
 ;;=M1A.40X1^^109^1612^155
 ;;^UTILITY(U,$J,358.3,39018,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39018,1,3,0)
 ;;=3^Gout, chron, secndry, unspec site, w/ tophus, oth
 ;;^UTILITY(U,$J,358.3,39018,1,4,0)
 ;;=4^M1A.40X1
 ;;^UTILITY(U,$J,358.3,39018,2)
 ;;=^5010994
 ;;^UTILITY(U,$J,358.3,39019,0)
 ;;=D89.89^^109^1612^103
 ;;^UTILITY(U,$J,358.3,39019,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39019,1,3,0)
 ;;=3^Disorders invlvng immune mechanism, NEC, oth, spec
 ;;^UTILITY(U,$J,358.3,39019,1,4,0)
 ;;=4^D89.89
 ;;^UTILITY(U,$J,358.3,39019,2)
 ;;=^5002458
 ;;^UTILITY(U,$J,358.3,39020,0)
 ;;=M12.30^^109^1612^199
 ;;^UTILITY(U,$J,358.3,39020,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39020,1,3,0)
 ;;=3^Palindromic rheumatism, unspec site
 ;;^UTILITY(U,$J,358.3,39020,1,4,0)
 ;;=4^M12.30
 ;;^UTILITY(U,$J,358.3,39020,2)
 ;;=^5010570
 ;;^UTILITY(U,$J,358.3,39021,0)
 ;;=M35.3^^109^1612^203
 ;;^UTILITY(U,$J,358.3,39021,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39021,1,3,0)
 ;;=3^Polymyalgia rheumatica
 ;;^UTILITY(U,$J,358.3,39021,1,4,0)
 ;;=4^M35.3
 ;;^UTILITY(U,$J,358.3,39021,2)
 ;;=^96292
 ;;^UTILITY(U,$J,358.3,39022,0)
 ;;=M33.20^^109^1612^204
 ;;^UTILITY(U,$J,358.3,39022,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39022,1,3,0)
 ;;=3^Polymyositis, organ involvement unspec
 ;;^UTILITY(U,$J,358.3,39022,1,4,0)
 ;;=4^M33.20
 ;;^UTILITY(U,$J,358.3,39022,2)
 ;;=^5011770
 ;;^UTILITY(U,$J,358.3,39023,0)
 ;;=M34.0^^109^1612^207
 ;;^UTILITY(U,$J,358.3,39023,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39023,1,3,0)
 ;;=3^Progressive systemic sclerosis
 ;;^UTILITY(U,$J,358.3,39023,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,39023,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,39024,0)
 ;;=E20.1^^109^1612^208
 ;;^UTILITY(U,$J,358.3,39024,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39024,1,3,0)
 ;;=3^Pseudohypoparathyroidism
 ;;^UTILITY(U,$J,358.3,39024,1,4,0)
 ;;=4^E20.1
 ;;^UTILITY(U,$J,358.3,39024,2)
 ;;=^100160
 ;;^UTILITY(U,$J,358.3,39025,0)
 ;;=L40.54^^109^1612^210
 ;;^UTILITY(U,$J,358.3,39025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39025,1,3,0)
 ;;=3^Psoriatic juvenile arthropathy
 ;;^UTILITY(U,$J,358.3,39025,1,4,0)
 ;;=4^L40.54
 ;;^UTILITY(U,$J,358.3,39025,2)
 ;;=^5009169
 ;;^UTILITY(U,$J,358.3,39026,0)
 ;;=I73.00^^109^1612^214
 ;;^UTILITY(U,$J,358.3,39026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39026,1,3,0)
 ;;=3^Raynaud's syndrome w/o gangrene
 ;;^UTILITY(U,$J,358.3,39026,1,4,0)
 ;;=4^I73.00
 ;;^UTILITY(U,$J,358.3,39026,2)
 ;;=^5007796
 ;;^UTILITY(U,$J,358.3,39027,0)
 ;;=N13.5^^109^1612^99
 ;;^UTILITY(U,$J,358.3,39027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39027,1,3,0)
 ;;=3^Crosng vessel & strict of ureter w/o hydronephr
 ;;^UTILITY(U,$J,358.3,39027,1,4,0)
 ;;=4^N13.5
 ;;^UTILITY(U,$J,358.3,39027,2)
 ;;=^5015580
 ;;^UTILITY(U,$J,358.3,39028,0)
 ;;=N13.6^^109^1612^211
 ;;^UTILITY(U,$J,358.3,39028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39028,1,3,0)
 ;;=3^Pyonephrosis
 ;;^UTILITY(U,$J,358.3,39028,1,4,0)
 ;;=4^N13.6
 ;;^UTILITY(U,$J,358.3,39028,2)
 ;;=^101552
 ;;^UTILITY(U,$J,358.3,39029,0)
 ;;=M06.9^^109^1612^215
 ;;^UTILITY(U,$J,358.3,39029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39029,1,3,0)
 ;;=3^Rheumatoid arthritis, unspec
 ;;^UTILITY(U,$J,358.3,39029,1,4,0)
 ;;=4^M06.9
 ;;^UTILITY(U,$J,358.3,39029,2)
 ;;=^5010145
 ;;^UTILITY(U,$J,358.3,39030,0)
 ;;=M35.01^^109^1612^226
 ;;^UTILITY(U,$J,358.3,39030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39030,1,3,0)
 ;;=3^Sicca syndrome w/ keratoconjunctivitis
 ;;^UTILITY(U,$J,358.3,39030,1,4,0)
 ;;=4^M35.01
 ;;^UTILITY(U,$J,358.3,39030,2)
 ;;=^5011787
 ;;^UTILITY(U,$J,358.3,39031,0)
 ;;=M35.00^^109^1612^227
 ;;^UTILITY(U,$J,358.3,39031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39031,1,3,0)
 ;;=3^Sicca syndrome, unspec
 ;;^UTILITY(U,$J,358.3,39031,1,4,0)
 ;;=4^M35.00
 ;;^UTILITY(U,$J,358.3,39031,2)
 ;;=^5011786
 ;;^UTILITY(U,$J,358.3,39032,0)
 ;;=M35.9^^109^1612^281
 ;;^UTILITY(U,$J,358.3,39032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39032,1,3,0)
 ;;=3^Systemic invlmnt of conn tiss, unspec
 ;;^UTILITY(U,$J,358.3,39032,1,4,0)
 ;;=4^M35.9
 ;;^UTILITY(U,$J,358.3,39032,2)
 ;;=^5011797
 ;;^UTILITY(U,$J,358.3,39033,0)
 ;;=M32.10^^109^1612^283
 ;;^UTILITY(U,$J,358.3,39033,1,0)
 ;;=^358.31IA^4^2
